Phase I/II Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Patients With Previously Treated Advanced Solid Tumors, Including Pancreatic Cancer
Summary
The purpose of this phase I/II trial is to evaluate the safety and efficacy of anti-PSCA CAR T cells (BPX-601) followed by rimiducid in patients with previously treated, PSCA-positive advanced solid tumors, including pancreatic cancer.
General Information
NCT#: NCT02744287
Study ID: BP-012
Trial Phase: Phase I/II
Trial Sponsor: Bellicum Pharmaceuticals
Therapies Used in This Trial: BPX-601, Rimiducid